Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Ends Supply of Moderna’s Original COVID Vaccine
February 13, 2023
- Japan Panel Recognizes 10 More Deaths Possibly Linked to COVID Jabs
February 13, 2023
- Japan Cancels 140 Million-Plus Dose Order of Novavax’s COVID Vaccine
February 13, 2023
- Expert Panel’s Proposal Likely to Involve “2-Stage” Reform, Touch on Funding Too: Chairman
February 10, 2023
- Pharma Trade Groups Stress Concern for Re-Pricing Debate over Xocova: Chuikyo
February 9, 2023
- Japan Panel OKs Next COVID Vaccine Rollout This Autumn, Winter
February 9, 2023
- Chuikyo Talks Over Sales Criteria to Trigger Possible Xocova Re-Pricing; Is 3-Month-Based Estimate an Overestimate?
February 9, 2023
- Japan Cabinet OKs Bill to Create Pandemic Response Agency
February 8, 2023
- MHLW Panel OKs 79 More Health Damage Claims for COVID-19 Vaccines
February 8, 2023
- MHLW Council’s Efforts to Address Drug Lag Led to 371 Approvals to Date: Minister
February 8, 2023
- Expert Panel Member Sakamaki Wants Pricing Overhaul to Push Generic Industry Consolidation
February 6, 2023
- SCARDA to Beef Up Efforts to Discover Technologies Outside Infectious Diseases: AMED President
February 3, 2023
- MHLW Scratching Head over High-Price Drug Issue, Lecanemab in Mind: Bureau Chief
February 2, 2023
- Chuikyo OKs Use of Multiple Comparators to Price Xocova, Upping of Reduction Cap Mooted for Re-Pricing
February 2, 2023
- Label Expansions for Nubeqa, Rinvoq, Imbruvica Now in Line for Approval
February 2, 2023
- J-TEC’s Cell Sheet for Vitiligo Up for MHLW Panel Review Feb. 13
February 1, 2023
- MHLW Health Policy Bureau to Bolster Staff for Pharma Industry Promotion: Director-General
January 31, 2023
- MHLW Set to Import Intranasal, High-Dose Seasonal Flu Vaccines
January 30, 2023
- Semaglutide in Line for March Approval as Obesity Drug, Precedex Too
January 30, 2023
- Panel OKs Japan’s First Abortion Pill, but Upper Organ to Review It Again after Public Comments
January 30, 2023
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…